Expect continuing gains from Baxter International

Expect continuing gains from Baxter International

Improved sales following an acquisition led to a 20.9% jump in revenue for this company during the most-recent quarter.

The medical device maker continues to enjoy strong demand for its products as hospitals and clinics resume regular procedures on easing of COVID-19 lockdowns and other restrictions… Read More

Three buys for post-pandemic returns

These three medical device makers continue to enjoy strong demand for their products as hospitals and clinics resume regular procedures on easing of COVID-19 lockdowns and other restrictions. While ongoing supply-chain problems add risk, we like their long-term prospects.
BAXTER INTERNATIONAL INC. $56 is a buy. The… Read More

Earnings rose 8.8% at Baxter International

Earnings rose 8.8% at Baxter International

The firm’s shares are down since April 2020, largely because hospitals postponed elective surgical procedures due to the COVID-19 pandemic. 

But now the pandemic is easing and demand for this firm’s products is rebounding. The company’s purchase of a hospital equipment maker should also position it… Read More

This acquisition is already paying off

BAXTER INTERNATIONAL INC. $75 is a buy. The company (New York symbol BAX; Conservative Growth Portfolio, Manufacturing & Industry sector; Shares outstanding: 503.5 million; Market cap: $37.8 billion; Price-to-sales ratio: 2.7; Dividend yield: 1.5%; TSINetwork Rating: Average; www.baxter.com) recently acquired Hill-Rom Holdings Inc. for $12.4 billion. Hill-Rom makes… Read More

Key acquisition to spur post-pandemic gains

Baxter’s shares are down about 15% since hitting $92 in April 2020. That’s largely because hospitals postponed elective surgical procedures due to the COVID-19 pandemic. Now that the pandemic is easing, demand for its products is rebounding. The company’s upcoming purchase of hospital equipment maker… Read More